Learn how managing high blood pressure and high cholesterol keeps your heart health in check and helps prevent liver issues such as MASH.

These organizations can help you educate yourself, spread awareness, and connect with the MASH community to help you better manage your health.

Bank of America upgraded Akero Therapeutics (NASDAQ:AKRO) on Thursday, citing what it called “game-changing” data the company disclosed from a mid-stage trial for its lead drug efruxifermin against ...

THURSDAY, Jan. 30, 2025 (HealthDay News) -- Weight-loss surgery can protect the liver health of patients with obesity and ...

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...

"Now, most people will have no symptoms, and the diagnosis is often picked up through a random blood test or a scan. But ...

(Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...

Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment.

We recently compiled a list of the 10 Firms Post Impressive Gains on Monday. In this article, we are going to take a look at ...

J.P. Morgan, Morgan Stanley and Jefferies are acting as joint book-running managers for the proposed offering. The securities ...